← SynDRA
BOCEPREVIR
SynDRA canonical compound SYN0006377 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · OTC |
|---|
| Primary target(s) | AKR1C3 | CMA1 | CTSA | CTSF | CTSK | CTSL | CTSS | CYP3A5 |
|---|
| Mechanism of action | HCV inhibitor |
|---|
| Indication | hepatitis C |
|---|
| Disease area | infectious disease |
|---|
All known targets
- CMA1
- CTSA
- CTSF
- CTSK
- CTSL
- CTSS
- AKR1C3
- CTSB
- CTSV
- CYP3A5
- ELANE
- HCV NS3/4A
Mechanisms of action (all sources)
- HCV inhibitor
- HCV NS3/4A MODULATOR
- NS3 INHIBITOR
- NS4A INHIBITOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- F2
- ACHE
- OPRM1
- HDAC6
- HRH3
- HTR1A
- HTR2B
- KCNH2
- KDR
- MAOA
- PDE3A
- ADORA1
- PDE4A
- PGR
- PLG
- PRSS1
- PTGS1
- SLC6A2
- SLC6A3
- SLC6A4
- ESR1
- DRD3
- DRD1
- CYP4F3
- ADORA3
- ADRA1A
- ADRA2A
- AKR1C2
- AKR1C4
- AR
- CELA1
- CHRM1
- CHRM2
- CYP1A1
- CYP1A2
- CYP2B6
- CYP2C19
- CYP2D6
- CYP2J2
- CYP3A4
Drug classes
- Cytochrome P450 3A4 Inhibitors
- HCV NS3/4A Protease Inhibitors
- Hepatitis C Virus NS3/4A Protease Inhibitor
- Cytochrome P450 3A5 Inhibitors
ATC classes
- J05A · DIRECT ACTING ANTIVIRALS
Cross-references
Synonyms
- VICTRELIS
- victrelis
- SCH 503034
- Sch 50304
- EBP-520
- SCH-503034
- Victrelis
- EBP 520
- UNII-89BT58KELH
- 89BT58KELH
- CHEBI:68621
- SCH503034
- boceprevirum
- RefChem:56897
- J05AP03
- MFCD22208555
- SCH 50304
- Boceprevir(>90%)
- BOC
- Boceprevir [USAN]
- Boceprevir [USAN:INN]
- C27H45N5O5
- HSDB 8081
- Victrelis(TM)
- Victrelis (TN)
- Boceprevir (Standard)
- Boceprevir & NM107
- BOCEPREVIR [MI]
- BOCEPREVIR [INN]
- Boceprevir (INN/USAN)
- BOCEPREVIR [VANDF]
- BOCEPREVIR [MART.]
- BOCEPREVIR [WHO-DD]
- BOCEPREVIR [EMA EPAR]
- SCHEMBL640836
- EBP520
- GTPL7876
Look up BOCEPREVIR in the interactive SynDRA portal →